CN102770426A - 作为蛋白激酶抑制剂的化合物和组合物 - Google Patents
作为蛋白激酶抑制剂的化合物和组合物 Download PDFInfo
- Publication number
- CN102770426A CN102770426A CN2011800081357A CN201180008135A CN102770426A CN 102770426 A CN102770426 A CN 102770426A CN 2011800081357 A CN2011800081357 A CN 2011800081357A CN 201180008135 A CN201180008135 A CN 201180008135A CN 102770426 A CN102770426 A CN 102770426A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- halogen
- substituted
- alkoxyl group
- cyanic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(N*)=NC=C(C=C(c1c(*)c(*)nc(NC=O)c1*)C(N1*)=O)C1=I Chemical compound *C(N*)=NC=C(C=C(c1c(*)c(*)nc(NC=O)c1*)C(N1*)=O)C1=I 0.000 description 6
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (22)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30181010P | 2010-02-05 | 2010-02-05 | |
US61/301,810 | 2010-02-05 | ||
PCT/US2011/023812 WO2011097526A1 (en) | 2010-02-05 | 2011-02-04 | Compounds and compositions as protein kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102770426A true CN102770426A (zh) | 2012-11-07 |
CN102770426B CN102770426B (zh) | 2016-03-23 |
Family
ID=43735167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201180008135.7A Expired - Fee Related CN102770426B (zh) | 2010-02-05 | 2011-02-04 | 作为蛋白激酶抑制剂的化合物和组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9181238B2 (zh) |
EP (1) | EP2531498B1 (zh) |
JP (1) | JP5728499B2 (zh) |
CN (1) | CN102770426B (zh) |
WO (1) | WO2011097526A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109078189A (zh) * | 2018-10-23 | 2018-12-25 | 黄泳华 | 含有蛋白激酶抑制剂与白藜芦醇的组合物 |
CN109157660A (zh) * | 2018-10-28 | 2019-01-08 | 黄泳华 | 含有蛋白激酶抑制剂与西地那非的组合物 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2531498B1 (en) * | 2010-02-05 | 2016-07-13 | Novartis AG | Compounds and compositions as protein kinase inhibitors |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
AU2014250836C1 (en) * | 2013-04-12 | 2019-01-17 | Asana Biosciences, Llc | Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways |
WO2014179498A1 (en) * | 2013-04-30 | 2014-11-06 | Genentech, Inc. | Serine/threonine kinase inhibitors |
WO2014206344A1 (en) | 2013-06-28 | 2014-12-31 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
WO2018146253A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
CA3086765A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1341098A (zh) * | 1999-01-13 | 2002-03-20 | 拜尔有限公司 | 用ω-羧基芳基取代的二苯脲作为raf激酶抑制剂 |
CN1863774A (zh) * | 2003-10-08 | 2006-11-15 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6358932B1 (en) | 1994-05-31 | 2002-03-19 | Isis Pharmaceticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US6037136A (en) | 1994-10-24 | 2000-03-14 | Cold Spring Harbor Laboratory | Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto |
US5717100A (en) | 1995-10-06 | 1998-02-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
WO1997044058A1 (en) | 1996-05-23 | 1997-11-27 | Applied Research Systems Ars Holding N.V. | Compounds that inhibit the binding of raf-1 or 14-3-3 proteins to the beta chain of il-2 receptor, and pharmaceutical compositions containing same |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US6187799B1 (en) | 1997-05-23 | 2001-02-13 | Onyx Pharmaceuticals | Inhibition of raf kinase activity using aryl ureas |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
US6204467B1 (en) | 1998-03-24 | 2001-03-20 | Ford Global Technologies, Inc. | Method and apparatus for resistive welding |
RU2319693C9 (ru) | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
AU2001285349A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The University Of Arkansas | Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2 |
CN101365682A (zh) | 2005-12-08 | 2009-02-11 | 千禧药品公司 | 具有激酶抑制活性的双环化合物 |
EP2076513A1 (en) | 2006-10-20 | 2009-07-08 | Irm Llc | Compositions and methods for modulating c-kit and pdgfr receptors |
EP2531498B1 (en) * | 2010-02-05 | 2016-07-13 | Novartis AG | Compounds and compositions as protein kinase inhibitors |
-
2011
- 2011-02-04 EP EP11703560.0A patent/EP2531498B1/en not_active Not-in-force
- 2011-02-04 US US13/577,209 patent/US9181238B2/en not_active Expired - Fee Related
- 2011-02-04 JP JP2012552123A patent/JP5728499B2/ja active Active
- 2011-02-04 WO PCT/US2011/023812 patent/WO2011097526A1/en active Application Filing
- 2011-02-04 CN CN201180008135.7A patent/CN102770426B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1341098A (zh) * | 1999-01-13 | 2002-03-20 | 拜尔有限公司 | 用ω-羧基芳基取代的二苯脲作为raf激酶抑制剂 |
CN1863774A (zh) * | 2003-10-08 | 2006-11-15 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109078189A (zh) * | 2018-10-23 | 2018-12-25 | 黄泳华 | 含有蛋白激酶抑制剂与白藜芦醇的组合物 |
CN109157660A (zh) * | 2018-10-28 | 2019-01-08 | 黄泳华 | 含有蛋白激酶抑制剂与西地那非的组合物 |
Also Published As
Publication number | Publication date |
---|---|
US9181238B2 (en) | 2015-11-10 |
US20130143899A1 (en) | 2013-06-06 |
JP2013518904A (ja) | 2013-05-23 |
CN102770426B (zh) | 2016-03-23 |
EP2531498B1 (en) | 2016-07-13 |
JP5728499B2 (ja) | 2015-06-03 |
EP2531498A1 (en) | 2012-12-12 |
WO2011097526A1 (en) | 2011-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102770426B (zh) | 作为蛋白激酶抑制剂的化合物和组合物 | |
CN105636958B (zh) | Dna‑pk抑制剂 | |
CN104379575B (zh) | 用于调节egfr活性的化合物和组合物 | |
CN104640852B (zh) | Dna‑pk抑制剂 | |
US20210163464A1 (en) | Pyridine compound | |
JP6468611B2 (ja) | キナーゼ阻害のためのヘテロアリール化合物 | |
CN110526912B (zh) | 用于激酶抑制的杂芳基化合物 | |
CN103958497B (zh) | 作为AXL和c‑MET激酶抑制剂的尿嘧啶衍生物 | |
CN104540809B (zh) | 成纤维细胞生长因子受体的抑制剂 | |
JP6863901B2 (ja) | キナーゼ阻害のためのヘテロアリール化合物 | |
TWI330183B (zh) | ||
CA3050188C (en) | Imidazopyrazine compounds, preparation methods and uses thereof | |
JP5581390B2 (ja) | Akt阻害剤 | |
JP2022531932A (ja) | ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法 | |
TW201000468A (en) | Quinoxaline-and quinoline-carboxamide derivatives | |
KR20020015060A (ko) | 축합 이미다졸 화합물 및 당뇨병 치료약 | |
TW200528111A (en) | Pyrido-and pyrimidopyrimidine derivatives | |
BR112012022650B1 (pt) | Derivados de imidazo[1,2-a]pirazina, seu uso no tratamento ou na prevenção de distúrbios e doenças neurológicos, psiquiátricos ou metabólicos, composição farmacêutica que os compreende processo de preparação da mesma | |
CN109641918A (zh) | 作为组蛋白去甲基化酶抑制剂的咪唑 | |
CN106928219A (zh) | 含氮稠杂环化合物、制备方法、中间体、组合物和应用 | |
CN114605400A (zh) | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 | |
WO2016102493A1 (en) | Imidazopyridine ezh2 inhibitors | |
CN104557913B (zh) | 吡啶并嘧啶类化合物,其制备方法和用途 | |
TW200524937A (en) | Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands | |
US20220002287A1 (en) | Indazole kinase inhibitor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160104 Address after: Basel, Switzerland Applicant after: NOVARTIS AG Address before: British Bermuda, Hamilton Applicant before: Novartis international pharmaceuticals Ltd. Applicant before: Novartis AG Effective date of registration: 20160104 Address after: British Bermuda, Hamilton Applicant after: Novartis international pharmaceuticals Ltd. Applicant after: NOVARTIS AG Address before: British Bermuda, Hamilton Applicant before: IRM LLC Applicant before: Novartis AG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160323 Termination date: 20190204 |